18614107. METHODS FOR TREATING LYMPHOMA simplified abstract (NORTHWESTERN UNIVERSITY)

From WikiPatents
Jump to navigation Jump to search

METHODS FOR TREATING LYMPHOMA

Organization Name

NORTHWESTERN UNIVERSITY

Inventor(s)

Jaehyuk Choi of Chicago IL (US)

Jay Carroll Daniels of Chicago IL (US)

Jurgen Ruland of München (DE)

Tim Wartewig of Higganum CT (US)

METHODS FOR TREATING LYMPHOMA - A simplified explanation of the abstract

This abstract first appeared for US patent application 18614107 titled 'METHODS FOR TREATING LYMPHOMA

    • Simplified Explanation:**

The patent application describes a method for treating lymphoma by administering a PD-1 pathway agonist to a subject in need.

    • Key Features and Innovation:**
  • Treatment method for lymphoma using a PD-1 pathway agonist
  • Administering an effective amount of the agonist to the subject
  • Targeting the PD-1 pathway to treat the condition
    • Potential Applications:**

This technology could be used in the treatment of various types of lymphoma and potentially other cancers that involve the PD-1 pathway.

    • Problems Solved:**

The technology addresses the need for more effective treatments for lymphoma by targeting the PD-1 pathway, which plays a role in the immune response to cancer cells.

    • Benefits:**
  • Improved treatment options for lymphoma patients
  • Targeted therapy with potentially fewer side effects
  • Potential for increased survival rates and better outcomes
    • Commercial Applications:**

The technology could have significant commercial applications in the pharmaceutical industry, leading to the development of new cancer treatments and potentially improving patient outcomes.

    • Questions about Lymphoma Treatment with PD-1 Pathway Agonists:**

1. How does targeting the PD-1 pathway specifically help in treating lymphoma?

  - Targeting the PD-1 pathway can enhance the immune response against cancer cells, potentially leading to better treatment outcomes.

2. Are there any potential side effects associated with using PD-1 pathway agonists for lymphoma treatment?

  - While generally well-tolerated, PD-1 pathway agonists can cause immune-related side effects that need to be monitored during treatment.


Original Abstract Submitted

Provided herein is a method for treating a lymphoma in a subject in need thereof, comprising administering to the subject an effective amount of at least one PD-1 pathway agonist.